JANX008

Phase 1Small molecule

JANX008 is one of 4 small molecule programs targeting Advanced or Metastatic Solid Tumor Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid Tumor MalignanciesRecruiting

Advanced or Metastatic Solid Tumor MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Advanced or Metastatic Solid Tumor Malignancies

#DrugCompanyPhaseTrials

NP-G2-044

NNovita Pharmaceuticals, Inc.

Phase 2

1 2

Anti-PD-1 Therapy

NNovita Pharmaceuticals, Inc.

Phase 2

1 3

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

JANX008

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Advanced or Metastatic Solid Tumor Malignancies

NCT05783622

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumor Malignancies1 trial

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Recruiting·JJanux Therapeutics·Phase 1·NCT05783622·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JANX008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JANX008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JANX008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Janux Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJanux Therapeutics

JANX008

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News